George A. Digenis, Ph.D. - University of Kentucky - College of ...

More documents

Recommendations

Info

National Institutes of Health, "Preparation and Disposition of 11 C- D- and L-Amino Acids," $51,137 (3rd year renewal). Program for Applied Research Fertility Regulation, "Development of Methodology for Following Microcapsule Transcervical Transport in Baboons Utilizing External Scintigraphy," $10,966. Rowell Laboratories, "Cortenema Imaging Studies," $31,232 (lst year) Co- investigators: T. Foster and M. Jay (1983). INTERx, Merck, Sharp & Dohme Research Labs, "External Scintigraphy to Study Disposition of Rectal Dosage Form Matrix In Vivo," $20,000 (2nd year). Co-investigator: M. Jay. Ortho Pharmaceutical Corporation, "A Study on the Disposition of Vaginally Administered Nonoxynol-9 in Barren and Pregnant Rats," $10,000 (1983). "Ciba-Geigy Corporation, "External Scintigraphic Studies of Labeled Slow-K Tablets," $8,000 (1983). "Polyamines and Suicide Inhibitors in Tumor Imaging," $178,000 (direct costs) National Cancer Institute (1984-1987). "Tobacco and Health Research Institute, "Design and Synthesis of Specific Human Leukocyte Elastase Inhibitors", $55,139. (84-85). "GI Transit Times of Two Radiolabelled Placebo Formulations", $7,000, (1984). "Radionuclide Studies", $12,000, (G.A. Digenis and M.Jay), INTERx, Merck and Company (1984). "Neutron Activation Study", $15,000 (G.A. Digenis and M. Jay) $15,000, INTERx, Merck and Company (84-85). "Correlation of In Vitro and In Vivo Dissolution to Bioavailability by External Scintigraphy and Perturbed Angular Correlation", $45,000, (84-86). "Comparative Serum Concentratins of Theophylline in the Dog after Oral Administration of 111In-labelled Searle Theophylline CR-24 Preparation With and Without Food", $12,000, Searle Research and Developement, Division of G.D. Searle and Company (1985). "Radionuclide Studies" Interx, Merck and Company (continued), $20,025 (with Dr. M. Jay), (85-86). "Kinetics and Mechanism of Degradation of Aspartame", $25,000, Searle Research and Development (Searle Food Resources) (with Dr. A. Hussain) (1986). "Correlation of the GI Behavior of Erythromycin Beads to the Bioavailability of the Drugs", pending, (b) "Disposition of Calcium Carbonate After Oral Administration in Man", Warner- Lambert Co. $25,000 (1986) "(a)"Synthesis of C-Alprazolam", pending; (b)"Synthesis and Preliminary Disposition studies with 19 F-Flurbiprofen", The Upjohn Company, $110,000 (1986). "Assessment of a Bioadhesive Coating on the GI Transit Time of Pellets in Humans", $75,000 (1986), "Purchase of Gamma Camera", $25,000, Eli Lilly, Company (1986). "Novel Elastase Inhibitors: Mechanism and In Vivo Studies, $331,988 (3 years) National Institute of Health, Pending (1986). "Clinical Evaluation of Polymeric Dosage Forms of 5ASA", Eastman Kodak Company, $70,000 (with Dr. T. Foster) December, 1986 - June, 1988. "Studies on Polymerbound Peptidyl Carbamates", $43,500, Tobacco and Health Research Institute, July, 1987 - June 1988. 47
"Development of Novel Scintigraphy Techniques: Monitoring In Vivo Behavior with Gastric Retention Properties", $19,200, July, 1987 - June 1988. "Graduate Student Stipend: Novel Chemical Entities for Colonic Delivery", $11,000, Eli Lilly Company, December, 1987 - December, 1988. "Evaluation of Samarium 153 Labeled Enteric Coated Tablets in Man by External Scintigraphy", Hoffman-LaRoche Company, $18,000, December, 1987 - December, 1988. "Studies on Precorneal Retention of Multiparticulate Formulation by Gamma Scinti-graphy", Allergan Pharmaceutical Company, $83,000, December, 1987 - December, 1988. "Evaluation of Nivaldipine Oral Dosage Form in Dogs by External Scintigraphy", American Cyanamide Company, $14,030, January, 1988 - January, 1989. "Cefuroxime Bioavailability Studies", Glaxo Company, $8,337, January, 1988 - December 1989. "Studies on Polymer-Bound Peptidyl Carbamates as an Elastase Inhibitor", 7/1/88-6/30/89, Tobacco and Health Institute, $45,000 (2nd year). "Studies on Polymer-bound Peptidyl Carbamates as Elastase Inhibitors", PI-G.A. Digenis, Tobacco & Health Research Institute, 7/1/89-6/30-90 $45,698 (3rd year). "An Evaluation of the Effects of Food Tablet Size and Tablet Density on Gastric Residence and Small Bowel Transit Time of Placebo Tablets", Burroughs Wellcome Company, PI-G.A. Digenis, November 1, 1989 - October 31, 1990, $64,975. "Studies on the in vitro and in vivo Uptake of Polymeric Nanoparticles by Macrophages", Eastman (Sterling) Pharmaceutical Company, PI-G.A. Digenis, March 15, 1989 - February 1, 1990, $65,000. "Disposition of Human and Bovine Growth Hormone from a Sustained Release Formulation in the Dog", Eli Lilly Company, PI-G.A. Digenis, July 1, 1989 - June 30, 1990, $5,235. "Evaluation of Bovine Growth Hormone Using Gamma Scintigraphy in the Sheep", Eli Lilly and Company, PI-G.A. Digenis, July 1, 1989 - June 30, 1991, $65,000. "Alprazolam Studies", Upjohn Company, PI-G.A. Digenis, February 9, 1989 - December 9, 1989, $27,773. "Pre-corneal Retention of Artificial Tears", Allergan Pharmaceuticals, PI-G.A. Digenis, January 1, 1989 - June 30, 1989, $30,000. "Effect of Formulation on Ranitidine Absorption", Glaxo, Inc. PI-G.A. Digenis, September 1, 1989 - July 31, 1990, $42,960. "Disposition of N-vinylpyrrolidone After Oral Administration in the Rat", GAF Corporation, PI- G.A. Digenis, August 1, 1989 - July 31, 1991, $50,000. "An Evaluation of Ranitidine Bioavailability from Sustained Release Formulation in Healthy Adults", Glaxo, Inc., PI-G.A. Digenis, March 1, 1990 - February 28, 1991, $30,000. "Bioavailability of Nicergoline from a Transdermal Patch in Man", P.I.-G.A. Digenis, April 1, 1990 - March 31, 1991, Vectorpharma, $65,000. "The Disposition of CGP 43371 Following an 800mg Oral Dose to Healthy Males", P.I. G.A. Digenis, April 15, 1991 - August 14, 1992, Ciba Geigy Company, $82,349. "Studies on Metabolism", P. I. G.A. Digenis, April 15, 1991 - April 14, 1992, 3M Pharmaceuticals, $5,000. "An Evaluation of Ranitidine Bioavailability from Sustained Release Formulation in Healthy Adults", Glaxo, Inc., P.I.-G.A. Digenis, August 1, 1991 - August 1, 1993, $49,000. 48
Page 1 and 2: 1 Curriculum Vitae George A. Digeni
Page 3 and 4: 2 1967-70 Assistant Professor of Ma
Page 5 and 6: 4 IX. ADMINISTRATIVE ACTIVITY AND U
Page 7 and 8: "Use of Technetium and Other Radioa
Page 9 and 10: "Studies on the Interaction of PVP-
Page 11 and 12: "Systematic Approach in Developing
Page 13 and 14: "Disposition and Pharmacokinetics o
Page 15 and 16: "Latest News on Small Intestinal Tr
Page 17 and 18: Technol, Inc., Ft. Worth, TX, "Firs
Page 19 and 20: 2. Digenis, G.A., Abou-Chaar, C.I.
Page 21 and 22: 36. Digenis, G.A., Shakhshir, S., M
Page 23 and 24: 69. Digenis, G.A., "Toxicology Stud
Page 25 and 26: 97. Tsuji, K., Agha, B.J., Shinogi,
Page 27 and 28: 127. Digenis, G.A., Sandefer, E.P.,
Page 29 and 30: [ 11 C]Alprazolam: an Agonist for t
Page 31 and 32: 182. Gao, Z.J., Hussain, M.D., Moth
Page 33 and 34: 32 Author of Pharmacy Books and Cha
Page 35 and 36: "Tissue Distribution of D-Leucine-1
Page 37 and 38: "In Vivo Behavior of Multiparticula
Page 39 and 40: Pharmaceutical Scientists, San Anto
Page 41 and 42: Miami Beach, FL, November 5-9, 1995
Page 43 and 44: "Use of Clinical Gamma Scintigraphy
Page 45 and 46: 44 Funded Grants "Study of Factors
Page 47: "Chemically Active Filters for Modi
Page 51 and 52: "An evaluation of GI transit and bi
Page 53 and 54: 52 Ph.D.-Graduated Under Dr. G.A. D
Page 55: 54 30. Eric J. Dadey "Development o

George A. Digenis, Ph.D. - University of Kentucky - College of ...

Create successful ePaper yourself

Delete template?

Save as template?